ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

HALO vs JNJ // 10Y YIELD & FRED MACRO BETA

Halozyme Therapeutics Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: HALO 5 — JNJ 9
▲ 10Y YIELD & FRED MACRO BETA LEADER: JNJ
macro-sensitivity
1.08
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HALO VS. JNJ) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC HALO JNJ SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 83.60% 67.90% +15.70 HALO /gross-margins <GO>
Return on Invested Capital (ROIC) 18.00% 25.50% -7.50 JNJ /roic <GO>
EV/EBITDA & P/E Valuation 35.6x 18.5x +17.10 JNJ /valuation <GO>
Free Cash Flow Yield 4.33% 2.97% +1.36 HALO /fcf-yield <GO>
Operating Margin 33.60% 34.70% -1.10 JNJ /operating-margins <GO>
Net Profit Margin 22.70% 28.50% -5.80 JNJ /net-margins <GO>
Revenue Growth (YoY) 37.60% 6.00% +31.60 HALO /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 5.11 5.59 -0.48 JNJ /balance-sheet <GO>
Piotroski F-Score Quality 7/9 8/9 -1.00 JNJ /piotroski-score <GO>
Options Implied Move & Put/Call Skew 6.50% 7.20% -0.70 HALO /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 78.7 60.4 +18.37 HALO /rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE 0.88 1.08 -0.20 JNJ /macro-sensitivity <GO>
Forward P/E Multiple 39.5x 23.0x +16.50 JNJ /forward-pe <GO>
Enterprise Scale & Market Cap $14.89B $662.49B -$647.60B JNJ /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR HALO REV JNJ REV HALO GROSS % JNJ GROSS % HALO FCF JNJ FCF
FY 2025 $1.40B $94.19B 83.6% 67.9% $644.6M $19.70B
FY 2024 $1.02B $88.82B 84.3% 69.1% $468.4M $19.84B
FY 2023 $829.3M $85.16B 44.0% 44.0% $351.3M $18.96B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HALO // BETA 0.88
JNJ // BETA 1.08